Literature DB >> 20668053

The blockade of adenosine deaminase ameliorates chronic experimental colitis through the recruitment of adenosine A2A and A3 receptors.

Luca Antonioli1, Matteo Fornai, Rocchina Colucci, Oriana Awwad, Narcisa Ghisu, Marco Tuccori, Federico Da Settimo, Concettina La Motta, Gianfranco Natale, Emiliano Duranti, Agostino Virdis, Corrado Blandizzi.   

Abstract

Adenosine modulates immune/inflammatory reactions. This study investigates the expression of adenosine deaminase in the inflamed colon, the effects of adenosine deaminase inhibitors on established colitis, and the recruitment of adenosine receptors by endogenous adenosine after adenosine deaminase blockade. Adenosine deaminase expression was determined by Western blot. The effects of 4-amino-2-(2-hydroxy-1-decyl)pyrazole[3,4-d]pyrimidine (APP; a novel adenosine deaminase inhibitor), erythro-9-(2-hydroxy-3-nonyl)adenine (EHNA; a reference adenosine deaminase inhibitor), dexamethasone, and selective adenosine receptor antagonists were tested in rats with 2,4-dinitrobenzenesulfonic acid-induced colitis. Systemic (food intake, body and spleen weight) and colonic [macroscopic/microscopic damage, tumor necrosis factor-α (TNF-α), interleukin-6 (IL-6), and malondialdehyde (MDA)] inflammatory parameters were assessed. Test drugs were administered intraperitoneally for 6 days, starting at day 5 from colitis induction. Adenosine deaminase was detected in normal colon, and its expression was increased in inflamed tissues. Colitis was associated with decreased food intake and body weight, augmented spleen weight, and increased levels of colonic TNF-α, IL-6, and MDA. APP or EHNA, but not dexamethasone, improved food intake and body weight. APP, EHNA, and dexamethasone counteracted the increments of spleen weight, ameliorated macroscopic and microscopic indexes of inflammation, and reduced TNF-α, IL-6, and MDA levels. The beneficial effects of APP and EHNA on inflammatory parameters were prevented by the pharmacological blockade of A(2A) or A(3) receptors, but not A(1) or A(2B). The present results show that: 1) bowel inflammation is associated with an enhanced adenosine deaminase expression; and 2) the anti-inflammatory actions of adenosine deaminase inhibitors against chronic established colitis depend on the sparing of endogenous adenosine, leading to enhanced A(2A) and A(3) receptor activation.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20668053     DOI: 10.1124/jpet.110.171223

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  25 in total

Review 1.  The Purinergic System as a Pharmacological Target for the Treatment of Immune-Mediated Inflammatory Diseases.

Authors:  Luca Antonioli; Corrado Blandizzi; Pál Pacher; György Haskó
Journal:  Pharmacol Rev       Date:  2019-07       Impact factor: 25.468

2.  Unveiling the binding mode of adenosine deaminase inhibitors to the active site of the enzyme: implication for rational drug design : presented by Maria P. Abbracchio.

Authors:  Maria Letizia Trincavelli
Journal:  Purinergic Signal       Date:  2013-03       Impact factor: 3.765

3.  Colonic motor dysfunctions in a mouse model of high-fat diet-induced obesity: an involvement of A2B adenosine receptors.

Authors:  Luca Antonioli; Carolina Pellegrini; Matteo Fornai; Erika Tirotta; Daniela Gentile; Laura Benvenuti; Maria Cecilia Giron; Valentina Caputi; Ilaria Marsilio; Genny Orso; Nunzia Bernardini; Cristina Segnani; Chiara Ippolito; Balázs Csóka; Zoltán H Németh; György Haskó; Carmelo Scarpignato; Corrado Blandizzi; Rocchina Colucci
Journal:  Purinergic Signal       Date:  2017-08-14       Impact factor: 3.765

4.  Gs-coupled adenosine receptors differentially limit antigen-induced mast cell activation.

Authors:  Xiaoyang Hua; Kelly D Chason; Corey Jania; Tatiana Acosta; Catherine Ledent; Stephen L Tilley
Journal:  J Pharmacol Exp Ther       Date:  2012-11-13       Impact factor: 4.030

5.  Anti-inflammatory effect of a novel locally acting A2A receptor agonist in a rat model of oxazolone-induced colitis.

Authors:  L Antonioli; A El-Tayeb; C Pellegrini; M Fornai; O Awwad; G Giustarini; G Natale; L Ryskalin; Z H Németh; C E Müller; C Blandizzi; R Colucci
Journal:  Purinergic Signal       Date:  2017-11-08       Impact factor: 3.765

Review 6.  Purinergic signalling in the gastrointestinal tract and related organs in health and disease.

Authors:  Geoffrey Burnstock
Journal:  Purinergic Signal       Date:  2013-12-04       Impact factor: 3.765

7.  Preclinical Development of FA5, a Novel AMP-Activated Protein Kinase (AMPK) Activator as an Innovative Drug for the Management of Bowel Inflammation.

Authors:  Luca Antonioli; Carolina Pellegrini; Matteo Fornai; Laura Benvenuti; Vanessa D'Antongiovanni; Rocchina Colucci; Lorenzo Bertani; Clelia Di Salvo; Giorgia Semeghini; Concettina La Motta; Laura Giusti; Lorenzo Zallocco; Maurizio Ronci; Luca Quattrini; Francesco Angelucci; Vito Coviello; Won-Keun Oh; Quy Thi Kim Ha; Zoltan H Németh; Gyorgy Haskó; Corrado Blandizzi
Journal:  Int J Mol Sci       Date:  2021-06-13       Impact factor: 5.923

8.  Interplay between colonic inflammation and tachykininergic pathways in the onset of colonic dysmotility in a mouse model of diet-induced obesity.

Authors:  Luca Antonioli; Valentina Caputi; Matteo Fornai; Carolina Pellegrini; Daniela Gentile; Maria Cecilia Giron; Genny Orso; Nunzia Bernardini; Cristina Segnani; Chiara Ippolito; Balázs Csóka; György Haskó; Zoltán H Németh; Carmelo Scarpignato; Corrado Blandizzi; Rocchina Colucci
Journal:  Int J Obes (Lond)       Date:  2018-08-06       Impact factor: 5.095

9.  Relevance of TNBS-colitis in rats: a methodological study with endoscopic, histologic and Transcriptomic [corrected] characterization and correlation to IBD.

Authors:  Øystein Brenna; Marianne W Furnes; Ignat Drozdov; Atle van Beelen Granlund; Arnar Flatberg; Arne K Sandvik; Rosalie T M Zwiggelaar; Ronald Mårvik; Ivar S Nordrum; Mark Kidd; Björn I Gustafsson
Journal:  PLoS One       Date:  2013-01-31       Impact factor: 3.240

10.  Adenosine A2A receptor activation reduces recurrence and mortality from Clostridium difficile infection in mice following vancomycin treatment.

Authors:  Yuesheng Li; Robert A Figler; Glynis Kolling; Tara C Bracken; Jayson Rieger; Ralph W Stevenson; Joel Linden; Richard L Guerrant; Cirle Alcantara Warren
Journal:  BMC Infect Dis       Date:  2012-12-10       Impact factor: 3.090

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.